Get access

A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease§


  • Relevant conflicts of interest/financial disclosures: The educational grant from UCB Pharma funding this research contributed to the salaries of Kitty K. Wong and Jane E. Alty during the conduct of the study.

  • The research was supported by an educational grant from UCB Pharma.

  • §

    Full financial disclosures and author roles may be found in the online version of this article.



This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease.


Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period.


Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05).


Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. © 2011 Movement Disorder Society